WallStreetZenWallStreetZen

NASDAQ: CYCN
Cyclerion Therapeutics Inc Stock

$3.50+0.28 (+8.7%)
Updated Apr 19, 2024
CYCN Price
$3.50
Fair Value Price
$6.88
Market Cap
$9.49M
52 Week Low
$1.75
52 Week High
$6.75
P/E
-1.56x
P/B
0.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.26M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$21M
Beta
1.27
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CYCN Overview

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYCN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CYCN ($3.50) is undervalued by 49.13% relative to our estimate of its Fair Value price of $6.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CYCN ($3.50) is significantly undervalued by 49.13% relative to our estimate of its Fair Value price of $6.88 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CYCN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYCN due diligence checks available for Premium users.

Be the first to know about important CYCN news, forecast changes, insider trades & much more!

CYCN News

Valuation

CYCN fair value

Fair Value of CYCN stock based on Discounted Cash Flow (DCF)
Price
$3.50
Fair Value
$6.88
Undervalued by
49.13%
CYCN ($3.50) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYCN ($3.50) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYCN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CYCN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.56x
Industry
15.81x
Market
40.51x

CYCN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
5.74x
CYCN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CYCN's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.7M
Profit Margin
0%
CYCN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$13.4M
Liabilities
$2.1M
Debt to equity
0.19
CYCN's short-term assets ($8.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYCN's short-term assets ($8.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYCN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYCN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.5M
Investing
$0.0
Financing
$0.0
CYCN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CYCN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CYCN$9.49M+8.76%-1.56x0.84x
AEZS$9.47M-0.36%-0.57x0.52x
BCDA$9.62M-4.51%-0.65x-6.00x
CMMB$9.66M-2.86%-0.33x0.57x
BRTX$9.27M-4.86%-0.40x0.80x

Cyclerion Therapeutics Stock FAQ

What is Cyclerion Therapeutics's quote symbol?

(NASDAQ: CYCN) Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol CYCN. Cyclerion Therapeutics stock quotes can also be displayed as NASDAQ: CYCN.

If you're new to stock investing, here's how to buy Cyclerion Therapeutics stock.

What is the 52 week high and low for Cyclerion Therapeutics (NASDAQ: CYCN)?

(NASDAQ: CYCN) Cyclerion Therapeutics's 52-week high was $6.75, and its 52-week low was $1.75. It is currently -48.15% from its 52-week high and 100% from its 52-week low.

How much is Cyclerion Therapeutics stock worth today?

(NASDAQ: CYCN) Cyclerion Therapeutics currently has 2,710,096 outstanding shares. With Cyclerion Therapeutics stock trading at $3.50 per share, the total value of Cyclerion Therapeutics stock (market capitalization) is $9.49M.

Cyclerion Therapeutics stock was originally listed at a price of $250.00 in Mar 18, 2019. If you had invested in Cyclerion Therapeutics stock at $250.00, your return over the last 5 years would have been -98.6%, for an annualized return of -57.42% (not including any dividends or dividend reinvestments).

How much is Cyclerion Therapeutics's stock price per share?

(NASDAQ: CYCN) Cyclerion Therapeutics stock price per share is $3.50 today (as of Apr 19, 2024).

What is Cyclerion Therapeutics's Market Cap?

(NASDAQ: CYCN) Cyclerion Therapeutics's market cap is $9.49M, as of Apr 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cyclerion Therapeutics's market cap is calculated by multiplying CYCN's current stock price of $3.50 by CYCN's total outstanding shares of 2,710,096.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.